SRR27320690
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 56.08333333
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.330
- ANGIOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- MYOGENESIS+0.170
- WNT_BETA_CATENIN_SIGNALING+0.160
- ALLOGRAFT_REJECTION+0.090
- INFLAMMATORY_RESPONSE+0.070
- APICAL_JUNCTION+0.050
- UV_RESPONSE_DN+0.000
- COAGULATION-0.020
Top 10 suppressed
- MTORC1_SIGNALING-0.470
- MYC_TARGETS_V1-0.470
- PROTEIN_SECRETION-0.450
- CHOLESTEROL_HOMEOSTASIS-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.370
- E2F_TARGETS-0.360
- OXIDATIVE_PHOSPHORYLATION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- ANDROGEN_RESPONSE-0.330
- ESTROGEN_RESPONSE_LATE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013529 | — | cohortMD2 | 0.853 |
| 2 | a545f8c1-39e3-48cc-8c22-897c5d3a21ea | — | — | 0.849 |
| 3 | SRR1313107 | — | F | 0.848 |
| 4 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.847 |
| 5 | MBCProject_2661_T2_RNA | — | A | 0.846 |
| 6 | C3N-00175 | — | cohortA1 | 0.844 |
| 7 | BS_4W68NV3M | Med | Medulloblastoma | 0.843 |
| 8 | TCGA-44-A4SU-01A-11R-A24X-07 | — | cohortA1 | 0.842 |
| 9 | SRR8942982 | — | — | 0.836 |
| 10 | AUR-AFE6-TTM2-A-1-1-R-A742-41 | — | D | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |